Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: a simulation study.

Watanabe T, Maeda K, Nakai C, Sugiyama Y.

J Pharm Sci. 2013 Sep;102(9):3196-204. doi: 10.1002/jps.23623. Epub 2013 Jun 10.

PMID:
23754337
3.
4.

In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.

Abuasal BS, Bolger MB, Walker DK, Kaddoumi A.

Mol Pharm. 2012 Mar 5;9(3):492-504. doi: 10.1021/mp200275j. Epub 2012 Feb 2.

PMID:
22264132
5.

Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.

Ito K, Kusuhara H, Sugiyama Y.

Pharm Res. 1999 Feb;16(2):225-31.

PMID:
10100307
6.

PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein.

Holmstock N, Gonzalez FJ, Baes M, Annaert P, Augustijns P.

Mol Pharm. 2013 Mar 4;10(3):1056-62. doi: 10.1021/mp300512r. Epub 2013 Feb 19.

7.

Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.

Dufek MB, Bridges AS, Thakker DR.

Drug Metab Dispos. 2013 Sep;41(9):1695-702. doi: 10.1124/dmd.113.052191. Epub 2013 Jul 2.

8.

Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.

Bruyère A, Declèves X, Bouzom F, Ball K, Marques C, Treton X, Pocard M, Valleur P, Bouhnik Y, Panis Y, Scherrmann JM, Mouly S.

Mol Pharm. 2010 Oct 4;7(5):1596-607. doi: 10.1021/mp100015x. Epub 2010 Aug 4.

PMID:
20604570
9.

Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values.

Tachibana T, Kato M, Sugiyama Y.

Pharm Res. 2012 Mar;29(3):651-68. doi: 10.1007/s11095-011-0579-2. Epub 2011 Sep 13.

PMID:
21913031
10.

Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

Cummins CL, Jacobsen W, Benet LZ.

J Pharmacol Exp Ther. 2002 Mar;300(3):1036-45.

11.

P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.

Dufek MB, Knight BM, Bridges AS, Thakker DR.

Drug Metab Dispos. 2013 Mar;41(3):642-50. doi: 10.1124/dmd.112.049965. Epub 2013 Jan 3.

12.

Functional interaction of intestinal CYP3A4 and P-glycoprotein.

Kivistö KT, Niemi M, Fromm MF.

Fundam Clin Pharmacol. 2004 Dec;18(6):621-6. Review.

PMID:
15548232
13.

Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.

Tachibana T, Kato M, Takano J, Sugiyama Y.

Curr Drug Metab. 2010 Nov;11(9):762-77. Review.

PMID:
21189139
14.

Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption.

Badhan R, Penny J, Galetin A, Houston JB.

J Pharm Sci. 2009 Jun;98(6):2180-97. doi: 10.1002/jps.21572.

PMID:
18855913
15.

Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor.

Kadono K, Akabane T, Tabata K, Gato K, Terashita S, Teramura T.

Drug Metab Dispos. 2010 Jul;38(7):1230-7. doi: 10.1124/dmd.109.029322. Epub 2010 Mar 30.

16.

In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp.

Mudra DR, Desino KE, Desai PV.

Curr Drug Metab. 2011 Oct;12(8):750-73. Review.

PMID:
21568936
18.

Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism.

Huang J, Si L, Jiang L, Fan Z, Qiu J, Li G.

Int J Pharm. 2008 May 22;356(1-2):351-3. doi: 10.1016/j.ijpharm.2007.12.028. Epub 2007 Dec 28.

PMID:
18242899
19.

Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine.

Suzuki H, Sugiyama Y.

Eur J Pharm Sci. 2000 Nov;12(1):3-12. Review.

PMID:
11121729
20.

In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.

Patel J, Buddha B, Dey S, Pal D, Mitra AK.

Am J Ther. 2004 Jul-Aug;11(4):262-77.

PMID:
15266218
Items per page

Supplemental Content

Write to the Help Desk